Companies similar to IMMUNEERING CORP CLASS A (IMRX)
Health Care · NASDAQ
IMMUNEERING CORP CLASS A (IMRX)'s closest peers include Amgen (AMGN), NOVARTIS AG (NVS), Lilly (Eli) (LLY), Pfizer (PFE), ASTRAZENECA PLC (AZN) and Revolution Medicines (RVMD). This peer set is drawn from IMRX's enriched company profile and is informational only — not financial advice.
Similar companies
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.24 (as of 2026-07-21) · market cap $195.6B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.87 (as of 2026-07-21) · market cap $228.2B
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,175.41 (as of 2026-07-21) · market cap $1.08T
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.94 (as of 2026-07-21) · market cap $141.5B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.34 (as of 2026-07-21) · market cap $195.3B
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.29 (as of 2026-07-21) · market cap $38.9B
Not quite? Describe exactly what you want →
Peers are drawn from IMRX's enriched profile (the same similarity signal the chat uses for "companies like IMRX"). See the full profile: IMMUNEERING CORP CLASS A (IMRX).
Last updated 2026-07-21.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.